Overview

Reduced-Intensity Allogeneic Hematopoietic Stem Cell Transplantation for Malignant Hematological Diseases

Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
To evaluate engraftment and toxicity of a reduced intensity preparative regimen for patients who receive a matched related or unrelated donor allogeneic stem cell transplant (ASCT) for malignant hematological diseases
Phase:
N/A
Details
Lead Sponsor:
University of Oklahoma
Treatments:
Alemtuzumab
Busulfan
Fludarabine
Fludarabine phosphate